IL249066A0 - Highly concentrated pharmaceutical formulations comprising anti cd20 antibody - Google Patents

Highly concentrated pharmaceutical formulations comprising anti cd20 antibody

Info

Publication number
IL249066A0
IL249066A0 IL249066A IL24906616A IL249066A0 IL 249066 A0 IL249066 A0 IL 249066A0 IL 249066 A IL249066 A IL 249066A IL 24906616 A IL24906616 A IL 24906616A IL 249066 A0 IL249066 A0 IL 249066A0
Authority
IL
Israel
Prior art keywords
antibody
pharmaceutical formulations
highly concentrated
concentrated pharmaceutical
highly
Prior art date
Application number
IL249066A
Other languages
Hebrew (he)
Other versions
IL249066B (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL249066(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL249066A0 publication Critical patent/IL249066A0/en
Publication of IL249066B publication Critical patent/IL249066B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL249066A 2009-09-11 2016-11-20 Highly concentrated pharmaceutical formulations comprising anti cd20 antibody IL249066B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170110 2009-09-11
PCT/EP2010/063271 WO2011029892A2 (en) 2009-09-11 2010-09-10 Highly concentrated pharmaceutical formulations

Publications (2)

Publication Number Publication Date
IL249066A0 true IL249066A0 (en) 2017-01-31
IL249066B IL249066B (en) 2018-02-28

Family

ID=43732866

Family Applications (2)

Application Number Title Priority Date Filing Date
IL218165A IL218165A (en) 2009-09-11 2012-02-16 Highly concentrated stable pharmaceutical formulations for subcutaneous administration of a pharmaceutically active anti-cd20 antibody
IL249066A IL249066B (en) 2009-09-11 2016-11-20 Highly concentrated pharmaceutical formulations comprising anti cd20 antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL218165A IL218165A (en) 2009-09-11 2012-02-16 Highly concentrated stable pharmaceutical formulations for subcutaneous administration of a pharmaceutically active anti-cd20 antibody

Country Status (42)

Country Link
US (5) US20110076273A1 (en)
EP (5) EP4218716A1 (en)
JP (4) JP5674788B2 (en)
KR (3) KR101782301B1 (en)
CN (2) CN104399075B (en)
AR (1) AR078161A1 (en)
AU (1) AU2010294186B2 (en)
BR (1) BR112012005017B8 (en)
CA (1) CA2771571C (en)
CL (1) CL2012000620A1 (en)
CO (1) CO6440527A2 (en)
CR (1) CR20120090A (en)
CY (1) CY1117941T1 (en)
DK (2) DK2475353T3 (en)
DO (2) DOP2012000064A (en)
EA (2) EA201792552A1 (en)
EC (1) ECSP12011722A (en)
ES (2) ES2953478T3 (en)
FI (1) FI3061445T3 (en)
GT (1) GT201200069A (en)
HK (2) HK1174553A1 (en)
HR (2) HRP20231019T1 (en)
HU (2) HUE062860T2 (en)
IL (2) IL218165A (en)
LT (1) LT3061445T (en)
MA (1) MA33592B1 (en)
MX (3) MX2012002861A (en)
MY (2) MY174009A (en)
NZ (2) NZ621448A (en)
PE (2) PE20151425A1 (en)
PH (1) PH12016501002A1 (en)
PL (2) PL2475353T3 (en)
PT (1) PT3061445T (en)
RS (1) RS54769B1 (en)
SG (1) SG179030A1 (en)
SI (2) SI3061445T1 (en)
SM (1) SMT201600176B (en)
TN (1) TN2012000101A1 (en)
TW (2) TWI515020B (en)
UA (1) UA104909C2 (en)
WO (1) WO2011029892A2 (en)
ZA (1) ZA201201605B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP3266453A1 (en) 2008-07-03 2018-01-10 Mayo Foundation for Medical Education and Research Treating cancer
RS56632B1 (en) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (en) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 Comprise the pharmaceutical composition of GLP-1 agonist and methionine
JP6199186B2 (en) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
CN107261154A (en) 2011-04-29 2017-10-20 西莱克塔生物科技公司 Tolerogenesis synthesizes nano-carrier
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (en) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Combination medicine used for blood glucose control in patients with type 2 diabetes
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130058963A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells
WO2013063516A1 (en) 2011-10-28 2013-05-02 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
MY171140A (en) 2012-01-27 2019-09-27 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
US20150239977A1 (en) * 2012-09-27 2015-08-27 Massachusetts Institute Of Technology Cd20- and egfr-binding proteins with enhanced stability
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
EP3967306A1 (en) 2012-10-01 2022-03-16 Mayo Foundation for Medical Education and Research Cancer treatments
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
JP2016508125A (en) * 2012-12-12 2016-03-17 テバ ファーマシューティカル インダストリーズ リミティド Fusion of human growth hormone and albumin, its formulation and use
WO2014113359A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR095372A1 (en) * 2013-03-12 2015-10-14 Teva Pharma INDUCTION THERAPY WITH RITUXIMAB FOLLOWED BY A THERAPY WITH GLATIRAMER ACETATE
BR112015022210A8 (en) * 2013-03-13 2018-01-23 Genentech Inc antibody formulations
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN110496099B (en) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 Liquid protein formulations comprising viscosity reducing agents
CN106170298B (en) * 2013-10-16 2024-01-09 前瞻疗法公司 Buffer formulations for improving antibody stability
EP3071181B1 (en) 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
MX2016008978A (en) 2014-01-09 2016-10-04 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives.
CN105899190B (en) 2014-01-09 2022-06-14 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
CN112957455A (en) 2014-01-09 2021-06-15 赛诺菲 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN113318239A (en) * 2014-06-13 2021-08-31 梅约医药教育及研究基金会 Treating lymphoma
KR20210125603A (en) 2014-06-16 2021-10-18 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Treating myelomas
CA2958145C (en) * 2014-07-16 2023-09-26 New York University Use of hyaluronidase for treatment of muscle stiffness
EP3189138A4 (en) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
EP3193932B1 (en) * 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of ac
MX2017007699A (en) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation.
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
CN104761645A (en) * 2015-04-30 2015-07-08 山东禹王制药有限公司 Alpha-interferon fusion protein preparation and application
DE102015107307B3 (en) * 2015-05-11 2016-09-08 Labor L + S Aktiengesellschaft Optical method for assaying hyaluronic acid
CN108136218B (en) * 2015-05-20 2022-12-13 詹森生物科技公司 anti-CD 38 antibodies for the treatment of light chain amyloidosis and other CD 38-positive hematologic malignancies
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
LT3124976T (en) * 2015-07-28 2018-12-27 F. Hoffmann-La Roche Ag Improved bacterial endotoxin test for the determination of endotoxins
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2016350717B2 (en) 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10702606B2 (en) 2015-12-10 2020-07-07 Menicon Co., Ltd. Peptide composition
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
JP7084308B2 (en) 2016-02-03 2022-06-14 アウトルック セラピューティクス，インコーポレイティド Buffer formulation to increase antibody stability
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Methods for improving the therapeutic index for a chemotherapeutic drug
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CA3029851A1 (en) * 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
IL301948B1 (en) * 2016-08-29 2024-05-01 Tiziana Life Sciences Plc Anti-cd3 antibody formulations
AU2017321798B2 (en) 2016-09-01 2023-06-15 Mayo Foundation For Medical Education And Research Methods and compositions for targeting T-cell cancers
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
JP2019526587A (en) 2016-09-06 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Methods for treating cancers expressing PD-L1
CN109890422A (en) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 Taxol-albumin-binding agent composition and the method for using and preparing the composition
EP3538136A1 (en) * 2016-11-10 2019-09-18 Translate Bio, Inc. Subcutaneous delivery of messenger rna
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN110869050B (en) * 2017-07-28 2024-07-02 豪夫迈·罗氏有限公司 Bispecific antibody formulations
CN107596349A (en) * 2017-10-26 2018-01-19 刘冬连 A kind of erythropoietin preparation formula of stabilization
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
CN107898756B (en) * 2017-12-22 2020-11-20 东曜药业有限公司 High-concentration nimotuzumab preparation for subcutaneous or intramuscular injection and preparation method and application thereof
TW202011995A (en) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 High concentration liquid antibody formulations
JP7475335B2 (en) * 2018-09-13 2024-04-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト CSF-1R antibody preparation
CN111202845A (en) * 2018-11-22 2020-05-29 上海医药集团股份有限公司 Pharmaceutical formulations comprising anti-CD 20 antibodies, methods of making and uses thereof
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
JP2023507053A (en) * 2019-10-12 2023-02-21 バイオ－セラ ソリューションズ リミテッド Anti-CD20 Antibody Preparations and Use of Anti-CD20 Antibodies for Treatment of CD20-Positive Diseases
IL293580A (en) * 2019-12-09 2022-08-01 Genentech Inc Anti-pd-l1 antibody formulations
CU20190104A7 (en) 2019-12-17 2021-08-06 Ct Inmunologia Molecular STABLE FORMULATION OF THE NIMOTUZUMAB ANTIBODY
KR20230129462A (en) * 2020-12-30 2023-09-08 상하이 바오 파마슈티컬스 컴퍼니 리미티드 Recombinant human hyaluronidase preparation and applications thereof
EP4326288A1 (en) 2021-04-21 2024-02-28 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN113855798A (en) * 2021-09-30 2021-12-31 佛山汉腾生物科技有限公司 anti-CD 20 antibody formulations
WO2023204554A1 (en) * 2022-04-20 2023-10-26 주식회사 알토스바이오로직스 Pharmaceutical composition comprising ocrelizumab and use thereof
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024025440A1 (en) * 2022-07-26 2024-02-01 Joint Stock Company "Biocad" Pharmaceutical composition of anti-cd20 antibody and use thereof

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2547556B2 (en) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 Liquid formulation of r-globulin
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
JPH04346934A (en) * 1991-05-24 1992-12-02 Green Cross Corp:The Liquid preparation of gamma-globulin
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
NZ258392A (en) * 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (en) * 1995-07-27 2013-09-24 Genentech Inc Stable isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
DE69739673D1 (en) 1996-11-27 2009-12-31 Genentech Inc Affinity Purification of Polypeptide Proteins on a Protein A Matrix
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
ATE458007T1 (en) * 1998-04-20 2010-03-15 Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODIES-DEPENDENT CELL-MEDIATED CYTOTOXICITY
SI1308455T1 (en) * 1998-05-06 2006-08-31 Genentech Inc A composition comprising anti-HER2 antibodies
CN1314917A (en) 1998-05-15 2001-09-26 伊姆克罗尼系统公司 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinase
EA004107B1 (en) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
MY155913A (en) * 1998-11-09 2015-12-15 Biogen Inc Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
WO2000027428A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
SI1189641T1 (en) 1999-06-25 2009-12-31 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001034194A1 (en) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
JP2003523771A (en) 2000-02-25 2003-08-12 ザ ガバメント オブ ザ ユナイテッド ステイツ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Anti-EGFRvIII scFv with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CA2404365A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
KR20030016250A (en) * 2000-04-25 2003-02-26 아이덱 파마슈티칼즈 코포레이션 Intrathecal administration of rituximab for treatment of central nervous system lymphomas
KR100480985B1 (en) 2000-05-19 2005-04-07 이수화학 주식회사 Humanized antibodies to the epidermal growth factor receptor
JP2004512262A (en) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション Non-radioactive anti-CD20 antibody / radiolabeled anti-CD22 antibody combination
ES2477996T3 (en) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing an antibody
MXPA03002262A (en) * 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
HU231090B1 (en) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002034790A1 (en) * 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
WO2002060485A2 (en) * 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
IL157946A0 (en) 2001-04-02 2004-03-28 Genentech Inc Combination therapy
CN100497389C (en) 2001-06-13 2009-06-10 根马布股份公司 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
DE10153197A1 (en) 2001-10-27 2003-05-08 Merck Patent Gmbh Metallic gloss pigment
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP3284753B1 (en) 2002-10-17 2019-06-05 Genmab A/S Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
US7402728B2 (en) * 2002-12-16 2008-07-22 Genentech, Inc. Transgenic mice expressing human CD20 and/or CD16
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
AU2004205802B2 (en) 2003-01-22 2009-11-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
SI1613350T1 (en) 2003-04-09 2009-08-31 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
KR101424624B1 (en) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 Drug Conjugate Composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1629001A2 (en) * 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
US20050032130A1 (en) * 2003-07-29 2005-02-10 Genentech, Inc. Neutralizing antibody assay and uses therefor
BRPI0414014A (en) 2003-08-26 2006-10-24 Becton Dickinson Co methods for intradermal delivery of therapeutic agents
MXPA06002134A (en) * 2003-08-29 2006-05-31 Genentech Inc Anti-cd20 therapy of ocular disorders.
WO2005044859A2 (en) * 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
JP2007514787A (en) * 2003-12-19 2007-06-07 ジェネンテック・インコーポレーテッド Detection of CD20 in the treatment of autoimmune diseases
WO2005061542A2 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in transplant rejection
BRPI0509419A (en) * 2004-04-16 2007-09-04 Genentech Inc enzyme-linked immunosorbent assay method, antibodies, hybridoma and immunoassay kit
AR049021A1 (en) * 2004-04-16 2006-06-21 Genentech Inc TREATMENT OF DISORDERS WITH AN ANTIBODY THAT JOINS CD20
US20050276803A1 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Method for augmenting B cell depletion
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20050271658A1 (en) 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
WO2005114218A2 (en) 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US20060024295A1 (en) * 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
KR20070029733A (en) * 2004-06-04 2007-03-14 제넨테크, 인크. Method for treating multiple sclerosis
JP2008507520A (en) 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド HER2 antibody composition
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
BRPI0515230A (en) * 2004-08-19 2008-07-15 Genentech Inc isolated polypeptides, antibodies and nucleic acids, compositions, expression vector, isolated host cells, method of producing an antibody, manufactured articles, methods of treatment and alleviating dysfunction, methods of making and selecting a polypeptide, antibody cd20 binding agent, isolated anti-her2 antibody and uses of an antibody
MX2007002855A (en) * 2004-09-08 2007-04-27 Genentech Inc Methods of using death receptor ligands and cd20 antibodies.
CN101048428A (en) 2004-09-08 2007-10-03 健泰科生物技术公司 Methods of using death receptor ligands and CD20 antibodies
BRPI0516297A (en) * 2004-10-05 2008-09-02 Genentech Inc Vasculitis treatment methods and articles of manufacture
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1824885A1 (en) * 2004-12-17 2007-08-29 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2006069403A2 (en) * 2004-12-22 2006-06-29 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
MX2007008218A (en) * 2005-01-13 2007-08-17 Genentech Inc Treatment method.
TW200638943A (en) 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (en) * 2005-04-15 2007-05-09 Genentech Inc TREATMENT OF INTESTINAL INFLAMMATORY DISEASE (IBD)
CN101203242A (en) * 2005-04-22 2008-06-18 健泰科生物技术公司 Method for treating dementia or alzheimer's disease by CD2O antibody
RU2007142523A (en) * 2005-05-18 2009-06-27 БИОГЕН ИДЕК Инк. (US) METHODS FOR TREATING FIBROUS CONDITIONS
WO2006127517A2 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
CN101379085B (en) * 2005-06-30 2013-03-27 Abbvie公司 IL-12/P40 binding proteins
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0615026A8 (en) 2005-08-19 2018-03-06 Abbott Lab double variable domain immunoglobulin and its uses
BRPI0615397B1 (en) 2005-08-26 2023-10-03 Roche Glycart Ag ANTI-CD20 ANTIBODY, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE THEREOF
US9726673B2 (en) * 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
KR20080104160A (en) 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 Anti-igf-1r human monoclonal antibody formulation
TWI414531B (en) 2006-10-12 2013-11-11 Genentech Inc Antibodies to lymphotoxin-alpha
US20090175847A1 (en) 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
KR20190140090A (en) * 2007-07-09 2019-12-18 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
US20110243931A1 (en) * 2007-09-02 2011-10-06 Thomas Friess Combination therapy with type i and type ii anti-cd20 antibodies
US20090214561A1 (en) * 2007-09-24 2009-08-27 David Robert Close Treatment method
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
RU2498991C2 (en) * 2007-10-30 2013-11-20 Дженентек, Инк. Purification of antibodies with cation-exchange chromatography
WO2009086072A2 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
CA2708869C (en) * 2007-12-21 2016-06-28 F. Hoffmann-La Roche Ag Antibody formulation
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ES2382058T3 (en) 2008-01-17 2012-06-04 Philogen S.P.A. Combination of a fusion protein of an antibody directed against the fibronectin-IL-2 EDB, and a B-lymphocyte-binding molecule, progenitors of B-lymphocytes and / or their cancerous counterparts
MX2010009647A (en) 2008-03-25 2010-09-28 Roche Glycart Ag Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas.
US20090269339A1 (en) 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
CN102149416B (en) 2008-09-10 2014-02-12 弗·哈夫曼-拉罗切有限公司 Delivery device for use with therapeutic drug
AR073295A1 (en) * 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
PE20110302A1 (en) 2008-09-19 2011-05-21 Hoffmann La Roche PHARMACEUTICAL FORMULATION OF AN ANTIBODY AGAINST P-SELECTIN
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2769221A1 (en) 2009-08-04 2011-02-10 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
EP4029881A1 (en) 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Subcutaneously administered anti-il-6 receptor antibody
WO2013031266A1 (en) 2011-08-26 2013-03-07 テルモ株式会社 Syringe and syringe housing container

Also Published As

Publication number Publication date
DOP2016000110A (en) 2016-08-15
KR101782195B1 (en) 2017-09-26
PH12016501002B1 (en) 2018-01-29
PE20121178A1 (en) 2012-09-06
TW201114449A (en) 2011-05-01
IL249066B (en) 2018-02-28
CN102686216B (en) 2014-11-05
PE20151425A1 (en) 2015-09-18
EP3064196A1 (en) 2016-09-07
ES2953478T3 (en) 2023-11-13
HRP20231019T1 (en) 2023-12-08
JP2013504540A (en) 2013-02-07
PL2475353T3 (en) 2016-10-31
DK2475353T3 (en) 2016-05-30
AU2010294186B2 (en) 2013-09-19
HUE062860T2 (en) 2023-12-28
ZA201201605B (en) 2019-09-25
EA201200475A1 (en) 2012-10-30
RS54769B1 (en) 2016-10-31
MA33592B1 (en) 2012-09-01
CA2771571A1 (en) 2011-03-17
CN104399075B (en) 2018-11-06
UA104909C2 (en) 2014-03-25
CL2012000620A1 (en) 2013-09-06
US10280227B2 (en) 2019-05-07
US20150086537A1 (en) 2015-03-26
GT201200069A (en) 2014-05-26
EA201792552A1 (en) 2018-09-28
EP4218715A1 (en) 2023-08-02
BR112012005017A2 (en) 2020-10-27
HUE029078T2 (en) 2017-02-28
PT3061445T (en) 2023-08-28
SG179030A1 (en) 2012-04-27
US20160137742A1 (en) 2016-05-19
US20210054092A1 (en) 2021-02-25
KR20170034441A (en) 2017-03-28
TWI515021B (en) 2016-01-01
DK3061445T3 (en) 2023-09-11
US20190367629A1 (en) 2019-12-05
PL3061445T3 (en) 2023-11-06
JP2017200924A (en) 2017-11-09
MY197773A (en) 2023-07-13
AU2010294186A1 (en) 2012-03-08
LT3061445T (en) 2023-09-25
CO6440527A2 (en) 2012-05-15
EP3061445A1 (en) 2016-08-31
JP5674788B2 (en) 2015-02-25
MX360432B (en) 2018-10-31
SI2475353T1 (en) 2016-08-31
CR20120090A (en) 2012-07-12
JP2015061839A (en) 2015-04-02
JP2020011962A (en) 2020-01-23
DOP2012000064A (en) 2012-05-31
KR20120051094A (en) 2012-05-21
TW201429506A (en) 2014-08-01
NZ598653A (en) 2014-03-28
MX360435B (en) 2018-10-31
WO2011029892A2 (en) 2011-03-17
US20110076273A1 (en) 2011-03-31
ECSP12011722A (en) 2012-04-30
JP6934919B2 (en) 2021-09-15
SMT201600176B (en) 2016-08-31
EP2475353A2 (en) 2012-07-18
MY174009A (en) 2020-03-03
PH12016501002A1 (en) 2018-01-29
CY1117941T1 (en) 2017-05-17
EP2475353B1 (en) 2016-04-13
HK1208176A1 (en) 2016-02-26
JP6364310B2 (en) 2018-07-25
TWI515020B (en) 2016-01-01
KR20140006112A (en) 2014-01-15
TN2012000101A1 (en) 2013-09-19
HRP20160807T1 (en) 2016-08-26
BR112012005017B8 (en) 2021-09-21
SI3061445T1 (en) 2023-10-30
EP3061445B1 (en) 2023-07-05
WO2011029892A3 (en) 2011-09-15
IL218165A (en) 2016-12-29
US10377831B2 (en) 2019-08-13
HK1174553A1 (en) 2013-06-14
CN104399075A (en) 2015-03-11
IL218165A0 (en) 2012-07-31
MX2012002861A (en) 2012-04-20
KR101782301B1 (en) 2017-09-26
EA031972B1 (en) 2019-03-29
CA2771571C (en) 2013-11-12
CN102686216A (en) 2012-09-19
BR112012005017B1 (en) 2021-09-08
AR078161A1 (en) 2011-10-19
FI3061445T3 (en) 2023-08-30
NZ621448A (en) 2015-07-31
EP4218716A1 (en) 2023-08-02
US10752696B2 (en) 2020-08-25
ES2574052T3 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
IL249066B (en) Highly concentrated pharmaceutical formulations comprising anti cd20 antibody
HK1221153A1 (en) Antibody drug conjugates
ZA201401779B (en) Antibody formulations
ZA201204459B (en) Formulations of antibody
ZA201204266B (en) Antibody formulation
ZA201106503B (en) Antibody formulation
ZA201203242B (en) Antibody formulation
HRP20141257T1 (en) Antibodies against her2 truncated variant ctf-611
EP2588141A4 (en) Antibody formulations
EP2575887A4 (en) Optimized drug conjugates
IL219617A0 (en) Pharmaceutical solid dosage form
GB0908905D0 (en) Pharmaceutical compounds
GB0922537D0 (en) Pharmaceutical preparation
EP2473168A4 (en) Pharmaceutical formulations for indibulin
GB201115173D0 (en) Pharmaceutical preparation
GB0906971D0 (en) Pharmaceutical preparation
GB201115179D0 (en) Pharmaceutical preparation
GB0910772D0 (en) Pharmaceutical
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations
GB0911699D0 (en) Pharmaceutical compounds
GB0913850D0 (en) Pharmaceutical compounds
GB0915678D0 (en) Pharmaceutical compounds
GB0916458D0 (en) Pharmaceutical compounds
GB0917677D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed